RenovoRx Inc
NASDAQ:RNXT
Intrinsic Value
RenovoRx, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for the local treatment of solid tumors. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of RNXT.
RenovoRx Inc's market capitalization is 20.5m USD.
RNXT stock price is 1.213 USD.
RNXT.
RNXT. Open DCF Valuation
RNXT. Open Relative Valuation
RNXT has upside potential of 306% compared to the average analyst price target.
Open Wall St Estimates
RNXT has negative Free Cash Flow for the last twelve months.
RNXT's short-term assets (1m USD) exceed its short-term liabilties (1m USD).
RNXT has negative Operating Income for the last twelve months.
RNXT has negative Net Income for the last twelve months.
RNXT's ROE (Return on Equity) for the past 12 months is negative and is equal to -648%.
RNXT's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -71 225%.
RNXT's long-term liabilties (4m USD) exceed its long-term assets (1m USD).
RNXT has negative three-year average ROE (Return on Equity): -171%. The company is not efficient at transforming stockholders' equity into net income.
RNXT has negative three-year average ROIC (Return on Invested Capital): -10 988%. The company is not efficient at using invested capital to generate operating income.
RNXT's D/E (Debt to Equity) is very low and is equal to 0.
RNXT's Altman Z-Score is very low and is equal to -60.73.
Fundamental Analysis
RenovoRx Inc
Balance Sheet Decomposition
RenovoRx Inc
| Current Assets | 1.5m |
| Cash & Short-Term Investments | 1.2m |
| Other Current Assets | 293k |
| Current Liabilities | 1.2m |
| Accounts Payable | 561k |
| Accrued Liabilities | 614k |
| Non-Current Liabilities | 3.3m |
| Other Non-Current Liabilities | 3.3m |
Earnings Waterfall
RenovoRx Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-11.4m
USD
|
|
Operating Income
|
-11.4m
USD
|
|
Other Expenses
|
1.2m
USD
|
|
Net Income
|
-10.2m
USD
|
Free Cash Flow Analysis
RenovoRx Inc
RNXT Profitability Score
Profitability Due Diligence
RenovoRx Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
RenovoRx Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
RNXT Solvency Score
Solvency Due Diligence
RenovoRx Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.
Score
RenovoRx Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RNXT Price Targets Summary
RenovoRx Inc
According to Wall Street analysts, the average 1-year price target for
RNXT
is 4.93 USD
with a low forecast of 3.535 USD and a high forecast of 7.35 USD.
Ownership
RNXT Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
RNXT Price
RenovoRx Inc
| Average Annual Return | -39.22% |
| Standard Deviation of Annual Returns | 9.48% |
| Max Drawdown | -96% |
| Market Capitalization | 20.5m USD |
| Shares Outstanding | 16 866 000 |
| Percentage of Shares Shorted | 0.11% |
Company Profile
RenovoRx Inc
Country
Industry
Market Cap
Dividend Yield
Description
RenovoRx, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for the local treatment of solid tumors. The company is headquartered in San Jose, California and currently employs 6 full-time employees. The company went IPO on 2021-08-17. The firm is focused on developing therapies for the local treatment of solid tumors. The firm's lead product candidate RenovoGem. Its other product candidate include Renovo Trans-Arterial Micro-Perfusion (RenovoTAMP), and RenovoCath delivery system. RenovoGem, is a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath. Its therapy platform, RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) is focused on optimizing drug concentration in solid tumors using small molecule chemotherapeutics that enable physicians to isolate segments of the vascular anatomy closest to tumors and force chemotherapy across the blood vessel wall to bathe these difficult-to-reach tumors in chemotherapy.
You don't have any saved screeners yet
